Predictions
Enochian Biosciences Inc
Start price
Target price
Perf. (%)
€4.36
04.10.23
04.10.23
-
04.10.24
04.10.24
-24.77%
11.12.23
11.12.23
Probably not worthwhile Investment
Capital Southwest Corp
Start price
Target price
Perf. (%)
€20.72
03.10.23
03.10.23
-
03.10.24
03.10.24
15.73%
31.01.24
31.01.24
Fate Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.94
02.10.23
02.10.23
-
02.10.24
02.10.24
-13.79%
15.10.23
15.10.23
Could be very worthwhile Investment >20% year
Sportsmans Wareh.ho.
Start price
Target price
Perf. (%)
€4.28
01.10.23
01.10.23
€4.50
30.09.25
30.09.25
11.68%
16.10.23
16.10.23
Could be very worthwhile Investment >20% year
Aldeyra Therapeutics Inc.
Start price
Target price
Perf. (%)
€6.42
01.10.23
01.10.23
€10.00
30.11.25
30.11.25
-73.55%
16.10.23
16.10.23
Could be very worthwhile Investment >20% year
Immunic Inc.
Start price
Target price
Perf. (%)
€1.37
01.10.23
01.10.23
€3.00
28.02.26
28.02.26
-13.40%
18.02.24
18.02.24
Could be very worthwhile Investment >20% year
Akero Therapeutics Inc
Start price
Target price
Perf. (%)
€47.80
01.10.23
01.10.23
€65.00
30.06.26
30.06.26
-71.13%
13.10.23
13.10.23
Could be very worthwhile Investment >20% year
Mithra Pharmaceuticals S.A.
Start price
Target price
Perf. (%)
€1.40
30.09.23
30.09.23
€1.00
30.09.24
30.09.24
-21.00%
14.10.23
14.10.23
Probably not worthwhile Investment
Bad rating
Little Investments for future growth
Risky balance sheet
Capricor Therapeutics Inc
Start price
Target price
Perf. (%)
€3.32
30.09.23
30.09.23
€1.00
30.09.24
30.09.24
-17.17%
14.10.23
14.10.23
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Low dividend yield expected
Deutsche Rohstoff AG
Start price
Target price
Perf. (%)
€31.20
27.09.23
27.09.23
€32.00
27.09.24
27.09.24
7.69%
18.10.23
18.10.23
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Rising EBIT margin expected
Fair valuation
MicroVision Inc
Start price
Target price
Perf. (%)
€2.11
27.09.23
27.09.23
€4.00
27.09.24
27.09.24
5.76%
23.11.23
23.11.23
Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
ShiftPixy Inc.
Start price
Target price
Perf. (%)
€0.89
27.09.23
27.09.23
-
27.09.24
27.09.24
-13.68%
30.09.23
30.09.23
Could be very worthwhile Investment >20% year
ShiftPixy Inc.
Start price
Target price
Perf. (%)
€1.07
27.09.23
27.09.23
-
27.09.24
27.09.24
-28.63%
30.09.23
30.09.23
Could be worthwhile Investment >10% per year
Intercept Pharmaceuticals
Start price
Target price
Perf. (%)
€17.61
26.09.23
26.09.23
-
26.09.24
26.09.24
-1.48%
30.09.23
30.09.23
Risky Investment
Super Micro Computer
Start price
Target price
Perf. (%)
€236.20
26.09.23
26.09.23
-
26.09.24
26.09.24
259.70%
15.02.24
15.02.24
DBAG Deutsche Beteiligungs AG
Start price
Target price
Perf. (%)
€31.10
26.09.23
26.09.23
-
26.09.24
26.09.24
-9.49%
31.01.24
31.01.24
Sientra Inc.
Start price
Target price
Perf. (%)
€2.52
25.09.23
25.09.23
€5.20
25.09.24
25.09.24
-23.41%
11.10.23
11.10.23
Could be very worthwhile Investment >20% year
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€1.02
21.09.23
21.09.23
-
21.09.24
21.09.24
-7.27%
01.10.23
01.10.23
Could be very worthwhile Investment >20% year
Paradox Interactive publ AB
Start price
Target price
Perf. (%)
€20.58
21.09.23
21.09.23
-
21.09.24
21.09.24
-19.73%
18.03.24
18.03.24
Limelight Networks Inc.
Start price
Target price
Perf. (%)
€0.88
21.09.23
21.09.23
-
21.09.24
21.09.24
-78.43%
15.02.24
15.02.24
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€1.25
20.09.23
20.09.23
-
20.09.24
20.09.24
-24.48%
02.10.23
02.10.23
Could be worthwhile Investment >10% per year
Vita 34 AG
Start price
Target price
Perf. (%)
€4.76
19.09.23
19.09.23
€6.00
19.09.24
19.09.24
-1.68%
30.09.23
30.09.23
Very Future proof/growth oriented business model
Market Leader or Top 3
Could be very worthwhile Investment >20% year
Rising EBIT margin expected
MicroVision Inc
Start price
Target price
Perf. (%)
€2.02
19.09.23
19.09.23
€4.00
19.09.24
19.09.24
4.43%
27.09.23
27.09.23
Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected